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ABSTRACT
Direct co-operation between sensitiser molecules BAD and NOXA in mediating 
apoptosis suggests that therapeutic agents which sensitise to BAD may complement 
agents which sensitise to NOXA. Dynamic BH3 profiling is a novel methodology that 
we have applied to the measurement of complementarity between sensitiser BH3 
peptide mimetics and therapeutic agents. Using dynamic BH3 profiling, we show that 
the agent TG02, which downregulates MCL-1, sensitises to the BCL-2-inhibitory BAD-
BH3 peptide, whereas the BCL-2 antagonist ABT-199 sensitises to MCL-1 inhibitory 
NOXA-BH3 peptide in acute myeloid leukaemia (AML) cells. At the concentrations 
used, the peptides did not trigger mitochondrial outer membrane permeabilisation 
in their own right, but primed cells to release Cytochrome C in the presence of an 
appropriate trigger of a complementary pathway. In KG-1a cells TG02 and ABT-199 
synergised to induce apoptosis. In heterogeneous AML patient samples we noted a 
range of sensitivities to the two agents. Although some individual samples markedly 
favoured one agent or the other, in the group as a whole the combination of TG02 
+ ABT-199 was significantly more cytotoxic than either agent individually. We 
conclude that dynamic NOXA and BAD BH3 profiling is a sensitive methodology for 
investigating molecular pathways of drug action and complementary mechanisms of 
chemoresponsiveness.
INTRODUCTION
The ability of therapeutics to kill leukaemia cells 
is in part dependent on the net effect of the interplay 
between pro-apoptotic and anti-apoptotic molecules. In 
particular, when sensitiser BCL-2 family proteins (such 
as BAD and NOXA) succeed in displacing activator 
proteins (such as BIM) from survival proteins (such as 
BCL-2 and MCL-1), the apoptotic effectors/executioners 
BAX and BAK activate mitochondrial outer membrane 
permeabilisation (MOMP) and the apoptotic cascade 
is set in motion [1, 2]. Thus the influence of BCL-2 
family pro-survival molecules depends on the extent to 
which they can be neutralized by pro-apoptotic binding 
partners [3, 4].
When overexpressed in acute myeloid leukaemia 
cells, the survival proteins BCL-2 and MCL-1 confer 
chemoresistance [3, 5-7]. Pro-apoptotic BAX and BAK 
apoptosis effector function is thought to require the 
simultaneous neutralisation of all expressed pro-survival 
BCL family members, such that if MCL-1 is inhibited, 
BCL-2 may prevent apoptosis and vice versa [3, 8, 9]. 
This relationship was shown at the mechanistic levels by 
the complementary apoptotic function of the two sensitiser 
proteins NOXA (which targets the labile BCL-2 family 
survival proteins MCL-1, BCL2A1 and BCL2A10) and 
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BAD (which targets BCL-2 and BCL-XL). NOXA and 
BAD together were toxic in a cellular assay where neither 
was effective individually [10].
Several researchers have indicated that an agent 
which targets BCL-2 can synergise with an agent 
that targets MCL-1 [11-13]. In the current report, we 
demonstrate roles for NOXA and BAD in this type of 
dual dependency. We build upon the complementary 
function described for NOXA and BAD and investigate 
whether a chemotherapeutic agent that mimics the MCL-1 
sensitising role of NOXA will co-operate with a BAD-
BH3 peptide to trigger MOMP. Likewise we investigate 
whether an agent that mimics the BCL-2 sensitising role 
of BAD will co-operate with a NOXA-BH3 peptide to 
trigger MOMP (Figure 1 – schematic diagram). Finally 
we investigate the effects of using the two agents together 
to target AML cells.
ABT-199 is a small molecule BH3 mimetic, 
selective for BCL-2 and orally bioavailable [14, 15]. 
TG02 is a novel multi-kinase inhibitor which exerts 
greatest activity against the cyclin dependent kinase 
CDK9 (IC50 3nM) [16]. CDK9 is permissive for 
transcription by phosphorylation of RNA polymerase 
II on serine 2 (RPIIS2), and in AML cells TG02 
treatment causes rapid RPIIS2 dephosphorylation, 
such that RNA synthesis is strongly inhibited [16-18] 
and proteins with a short half-life, such as MCL-1, are 
rapidly downregulated [16, 17]. Our findings indicate 
the ability of TG02 to co-operate with BAD, the ability 
of ABT-199 to co-operate with NOXA and the ability 
of the two chemotherapeutic agents to co-operate with 
each other to induce cytochrome C release and apoptosis 
in AML cells.
RESULTS
TG02 and ABT-199 have complementary BH3 
profiles
To select suitable cells for our experiments we first 
established dose responses to the agents individually 
in three cell lines – MV4.11, KG-1a and OCI-AML-3. 
Responses were evaluated at 24 hours by alamar blue 
assay. All 3 cell lines were sensitive to nanomolar 
concentrations of TG02 (Figure 2A), but OCI-AML-3 are 
all eradicated, whereas MV4.11 and KG1a curves flatten 
with approximately 40% of cells remaining viable. OCI-
AML3 cells were highly resistant to ABT-199 (Figure 
2B); MV4.11 were sensitive and KG1a had intermediate 
sensitivity. BCL-2 and MCL-1 protein expression was 
similar in all three cell lines (Figure 2C).
Exposure of cells to drugs has been shown to 
reduce the concentration of BIM-BH3 peptide needed to 
induce mitochondrial outer membrane permeabilisation 
(MOMP) in sensitive samples [19]. BAD and NOXA are 
Figure 1: Schematic diagram. In this simplified scenario, TG02 as well as endogenous NOXA suppress the pro-survival function of 
MCL-1 and maybe of additional labile BCL-2 family pro-survival proteins (LBPP) [17, 20, 40]. ABT-199 and endogenous BAD suppress 
the pro-survival function of BCL-2 [14, 20, 40]. Mitochondrial outer membrane permeabilisation (MOMP), cytochrome C release and 
subsequent apoptosis result from antagonism of pro-survival proteins. In some cell types, MOMP may arise from targeting either BCL-2 or 
MCL-1 alone, whereas some cells might require more than one survival molecule to be suppressed.
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Figure 2: Responses to TG02 and ABT-199 and complementary BH3 profiles in KG-1a, OCI-AML3 and MV4.11 cell 
lines. A-B. Cells were cultured at 5 X 105/ml for 24 hours with the indicated concentrations of compounds and responses were measured by 
alamar blue assay. C. BCL-2, and MCL-1 were measured by flow cytometry. MFI = mean fluorescence intensity. D-E. Cells were treated for 
4 hours with 100 nM TG02 or 500 nM ABT-199, permeabilised and treated for 1 hour with 23 μM NOXA-BH3 or with BAD-BH3 (0.3 μM 
in KG-1a and MV4.11, 3 μM in OCI-AML3) before fixation and labelling with Cytochrome C antibody for flow cytometry. The percentage 
of cells which had released cytochrome C, a measure of mitochondrial outer membrane permeabilisation, was measured on fluorochrome/
side scatter dot plots. Adjustments for peptide-induced cytochrome C release in untreated cells were made by calculating agent-specific 
release according to the formula in the Methods section. All experimental results are mean ± SD of 3-4 independent assays.
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sensitiser BH3 proteins which can trigger MOMP and 
apoptosis by releasing BIM from anti-apoptotic BCL-
2 family proteins. BAD specifically releases BIM from 
BCL-2, whereas NOXA targets MCL-1 [20]. Direct co-
operation between BAD and NOXA in inducing apoptosis 
has been reported [10], suggesting that therapeutic agents 
which sensitise to BAD may complement agents which 
sensitise to NOXA, (Figure 1), likely through increasing 
the BIM released. To investigate this further, we used 
BH3 profiling, a technique which measures cytochrome 
C release in response to peptides derived from BH3-only 
pro-apoptotic family members [2, 21]. The technique 
is illustrated in Supplementary Figure 1. Loss of MCL-
1 might be expected to release pro-apoptotic proteins 
which transfer to the remaining BCL-2 or BCLXL, and 
can be detected by increased sensitivity to their antagonist 
peptide BAD-BH3 [22]. We found that TG02 triggered 
cells for a nearly complete response after priming with 
BAD-BH3, but not NOXA-BH3 (Figure 2D). In KG1a 
cells, the specific RNA Polymerase II (RPII) inhibitor 
5,6-dicholoro-1-β-D-ribofuranoslybenzimidazole (DRB) 
was used at the previously determined IC50 [18] to 
determine whether the BAD-priming effect was generic to 
RPII inhibition and this was found to be the case (P<0.001, 
Supplementary Figure 2). ABT-199, in contrast to TG02, 
triggered MV4.11 and KG-1a cells to respond to the 
MCL-1 sensitiser NOXA-BH3 (Figure 2E) indicating that 
endogenous pro-apoptotic proteins released from BCL-2 
transfer to MCL-1 and thus render the cells sensitive to 
the MCL-1 antagonist NOXA. The residual capacity of 
KG-1a cells triggered with ABT-199 to respond to BAD-
BH3 was abrogated when ABT-737 (which targets BCL-
XL as well as BCL-2) was used as trigger, and this was 
associated with over-expression of BCL-XL in these cells 
(Supplementary Figure 2), likely providing an additional 
target for BAD-BH3. Strikingly, the TG02/BAD-BH3 
and ABT-199/NOXA-BH3 combinations were effective 
except in the case of OCI-AML3’s failure to respond to 
the ABT-199/NOXA-BH3 combination. As these cells 
were also insensitive to killing by ABT-199 (Figure 
2B), this suggested that only effective drugs would be 
complemented by the appropriate BH3 peptide and 
therefore the study was expanded, as described below.
Effects of TG02 AND ABT-199 in primary 
samples
To further explore the general applicability of 
complementary profiling, and whether the apparent 
correlation between priming and cell killing could be 
extended to primary cells, we turned our attention to 
samples from AML patients. Dynamic BH3 profiling using 
BAD-BH3 and NOXA-BH3 peptides illustrated that the 
preference for TG02 to sensitise to BAD and of ABT-199 
to sensitise to NOXA, shown above in AML cell lines, is 
also true of patient cells (Figure 3). As with the cell lines, 
the main implication is that there is residual capacity in 
these primary samples targeted by one agent to respond to 
a peptide antagonising a complementary survival pathway. 
The cytotoxicity of the drugs corresponded closely to the 
degree of complementary peptide priming. The example 
of sample P1 in Figure 3 (low cytotoxicity of ABT-199 
coupled with low NOXA-BH3 priming, as with the OCI-
AML-3 cells) suggests that, at the concentrations used, the 
peptides are not triggering MOMP in their own right, but 
prime the cells to release Cytochrome C in the presence of 
an appropriate trigger of a complementary pathway.
TG02 and ABT-199 synergise to induce apoptosis
The dynamic profiling data demonstrate that, when 
MCL-1 is targeted, the cells primed with BAD undergo 
MOMP and when BCL-2 is targeted, the cells primed with 
NOXA undergo MOMP. This shows that the cells have 
residual capacity, when targeted by one agent, to respond 
to a complementary pathway, and further suggests that 
TG02 might co-operate with ABT-199 in cells that are 
dependent on both BCL-2 and MCL-1. As preliminary 
investigation had shown limited efficacy of these 
compounds individually in KG-1a cells, this cell line was 
selected for analysis of a combinatorial approach. KG-
1a are multidrug resistant, CD34+, CD38 +/- cells which 
express negative-to low levels of BCL2A1 and BCL2L10 
(data not shown); thus MCL-1 is the only one of the 
three NOXA-targeting labile BCL-2 family pro-survival 
proteins to be significantly expressed in these cells. 
After 4 hours of treatment, TG02 down-regulates MCL-
1 (by 40%) but not BCL-2 (Figure 4A). The use of the 
caspase inhibitor Z-VAD indicates that the loss of MCL-1 
precedes caspase activation. The use of the proteasome 
inhibitor MG132 confirms that, in this cell line, MCL-1 
protein expression has the expected high dependence on 
proteasome-mediated degradation [23] (contributing to 
its short half-life) and we show the contrast with BCL-2, 
which is not subject to similar proteasomal degradation.
In the KG-1a cells, synergy was documented for the 
combination of TG02 with ABT-199, (Figure 4B). Briefly, 
using the median effects method of Chou and Talalay, a 
combination index (CI) of around 1.0 shows an additive 
relationship. Antagonism increases with increasing CI 
above 1.0 and synergy is reflected in a decreasing CI [24]. 
In the current study strongly synergistic combinations 
are characterised by low CIs, evident across several 
concentrations, decreasing with dose and reaching as 
low as 0.14 at the higher concentrations associated with 
cytotoxic (rather than/as well as cytostatic) effects. A series 
of additional assays suggested largely cytostatic effects 
for the single agents and confirmed that the combination 
induces apoptotic cell death (Figure 4C-4F). BAK and 
BAX are important components of the mitochondrial 
apoptotic pathway, through their ability to create 
oligomeric pores in the mitochondrial outer membrane 
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[1]. Exposure of activation-sensitive epitopes of BAK 
and BAX, measured by antibodies specific for activated 
conformations [25, 26], has previously been described 
in sensitive cells following exposure to the dual BCL-2/
BCL-XL inhibitor ABT-737 [27]. Moreover depletion 
of BAX or BAK confers resistance to TG02 [28] and 
ABT-737 [11], although ABT-199 has not been reported 
in this context. We found stronger induction of BAK 
activated conformation in cells treated with combinations 
compared to single agent treatment (Figure 4C), We also 
found strong induction of BAX activated conformation 
in cells treated with combinations, contrasted with single 
digit effects with single agent treatment (Figure 4D). 
Active caspase 3 and phosphatidylserine exposure were 
induced strongly by the combination, but weakly by the 
single agents (Figure 4E and 4F), indicative of largely 
growth-inhibitory effects of the agents used individually 
and apoptotic effects for the combination. In a control 
experiment, the caspase inhibitor Z-VAD did not 
inhibit BAX or BAK activation, but blocked caspase 3 
activation (data not shown). We further showed that the 
downregulation of MCL-1, previously noted with TG02 
alone, was delayed at 2 hours but unimpaired at 4 hours 
of the drug combination, although ABT-199 alone had no 
effect on this protein (Figure 4G).
Initial experiments comparing responses to TG02, 
ABT-199 and the combination in patient samples showed 
a wide range of responsiveness, as represented in Figure 
5A. Some samples responded strongly to TG02, others 
to ABT-199 and some to both drugs, such that it was not 
appropriate to standardise a dose ratio and thus formally 
assess synergy in this cohort. However, we investigated 
Figure 3: Dynamic BH3 responses in primary samples. Four patient samples were treated with 100 nM TG02 A, B. or 100 nM 
ABT-199 C, D. After 4 hours, cells were permeabilised and treated for 1 hour with 100 μM NOXA-BH3 or 0.3 μM BAD-BH3, before 
fixation and labelling with Cytochrome C antibody. A,C, BAD BH3 and NOXA BH3 bars show the percentage of cells which had released 
cytochrome C. Adjustments for peptide-induced cytochrome C release in untreated cells were made by calculating agent-specific release 
according to the formula in the Methods section. B,D, Toxicity bars refer to percentage loss of control viable cell number of each agent 
after 16-20 hours’ culture with drugs at 25 nM, relative to untreated cell number, measured by flow cytometry with 7-AAD and an internal 
standard for viable cell counting.
Oncotarget16225www.impactjournals.com/oncotarget
Figure 4: The combination of TG02 and ABT-199 synergises to induce apoptosis in KG-1a cells. A. KG-1a cells were 
treated for 45 minutes with 10 μM Z-VAD or 0.5 μM MG132 and for a further 4 hours with 100 nM TG02. Alterations in total MCL-1 and 
BCL-2 expression were measured by flow cytometry. MFI = mean fluorescence intensity. B. KG-1a cells were incubated for 18-22 hours 
with TG02 and ABT-199 at a fixed dose ratio of 1(TG02):20(ABT-199). Toxicity was measured by alamar blue. B(i). Dose-response curves; 
B(ii). shows the combination index distributions generated by the Calcusyn software. C-F. KG-1a cells were treated for 16-18 hours with 
100 nM TG02 and/or 500 nM ABT-199, and then fixed and permeabilised. (C) Percentage of cells with activated BAK; (D) Percentage of 
cells with activated BAX; (E) Percentage of cells with activated caspase 3; (F) Percentage of Annexin V positive cells. All experimental 
results (A-F) are mean ± SD of 3-4 independent assays. G. KG1a cells were treated with 100 nM TG02 and/or ABT-199 for the indicated 
times and analysed for MCL-1 and BCL-2 by Western Blotting. The band at 40 kDa represents the long (anti-apoptotic) variant of MCL-1. 
The barchart shows MCL-1L: actin ratios calculated by densitometry (for n=2 independent assays).
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Figure 5: The combination of TG02 and ABT-199 in patient cells. A. 16-20 hour responses to a range of concentrations of TG02, 
ABT-199 and the combination were measured by flow cytometric viable cell counting in the same four patient samples as had been used to 
generate Figure 3. The combination was used in the ratio TG02:ABT-199 1:2. X-axis labels T = nM TG02, A = nM ABT-199. B. 16 primary 
AML samples (including P1 to P4, as in Figures 3 and 5A) were treated for 16-20 hours in vitro with 12.5 nM TG02, 25 nM ABT-199 or 
the combination. Cytotoxicity was determined by flow cytometric viable cell counting. B(i). individual samples. B(ii). summary: median, 
interquartile range (boxes) and range (error bars) of 18 samples. * denotes P=0.001 in the Wilcoxon signed rank test. C. 18 primary AML 
samples were treated for 16-20 hours in vitro with 50 nM TG02 + 50 nM ABT-199 or 100 nM of the agents individually. Toxicity was 
determined by flow cytometric viable cell counting. The summary graph shows percentage decrease in viable cells. Median, interquartile 
range (boxes) and range (error bars) of 18 samples. ** denotes P=0.02, *** denotes P<0.001 in the Wilcoxon signed rank test. D. Active 
Bax was measured by flow cytometry at early timepoints after treatment with TG02 (pale grey squares) or ABT-199 (dark grey diamonds) 
(Mean + standard deviation for 4 samples). Cytotoxicity at 16-20 hours (marked 18 on the X axis) is also shown.
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the toxicity of the ABT-199 and TG02 combination in 
primary samples treated overnight with both low doses 
and high doses of the agents singly and in combination. 
With low doses - 12.5 nM TG02, 25 nM ABT-199, 
or the combination, we found the combination to be 
significantly more toxic than either agent individually 
(P=0.001 for both agents, Figure 5B). Some samples were 
markedly more sensitive to one agent than the other, and 
other samples were sensitive to both, indicating that in 
this heterogeneous disease, the combinatorial approach 
broadens the range of samples that can be effectively 
killed.
It might be argued that the effects of apoptosis-
inducing agents should be studied at high concentrations 
in order to document their abilities to eradicate the cells, 
so we also treated 18 primary samples with the higher 
concentrations of 50 nM TG02 + 50 nM ABT-199 or 
100 nM of the 2 agents individually. We showed that 
using either agent at 100 nM was overall less effective 
than the combination of 50 nM of each drug (Figure 5C). 
Another point of note is that whereas the toxicity of ABT-
199 reaches a plateau at around 25 nM, the toxicity of 
TG02 continues to increase, and the majority of cells are 
eradicated at 100 nM, as previously reported [17].
Active BAX was measured at early timepoints and 
showed that BAX activation can be seen as early as 2 
hours post ABT-199 treatment in sensitive samples and 4 
hours with TG02 (Figure 5D).
A combinatorial approach might be less 
therapeutically valuable if AML patient samples could be 
grouped into discrete groups of BCL-2 over-expressers and 
MCL-1 over-expressers, thereby stratifying this population 
into subsets potentially responsive to each drug as a single 
agent. We measured BCL-2 and MCL-1 using RNA from 
117 CD2+cell-depleted primary samples and show here that 
there is no trend for primary AML samples to group into 
distinct MCL1-over-expressing and BCL-2-overexpressing 
samples (Spearman’s rho = -0.11, not significant, Figure 6A). 
Figure 6: Primary cell survival in TG02-treated cells against BCL-2 and MCL-1 expression. A. Basal expression of BCL-2 
and MCL-1 relative to the housekeeping gene B2M measured by realtime PCR in 117 AML samples. B. BCL-2 and C., MCL-1 in samples 
for which the 48 hour in vitro response to TG02 had previously been determined [17].
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A similar lack of association has been reported by others 
at the protein level [29]. We have previously reported that 
sensitivity to TG02 varied among primary AML isolates 
[17]. We have now measured MCL-1 and BCL-2 in cells 
from this historical cohort and found that BCL-2 was 
associated with TG02 resistance (Figure 6B). There was no 
correlation between MCL-1 expression and TG02 sensitivity 
(Figure 6C).
DISCUSSION
BH3 sensitiser molecules BAD and NOXA co-
operate to induce apoptosis [10], as do NOXA and 
the BAD mimetic ABT-737 [30]. We determined the 
applicability of the BAD/NOXA co-operating interaction 
to two novel chemotherapeutic compounds, TG02 
and ABT-199, in Acute Myeloid Leukaemia. We used 
dynamic BH3 profiling – a methodology for dissecting 
mechanisms of apoptosis induction at the functional level 
through monitoring changes in the abilities of specific 
pro-apoptotic BH3 peptides to induce cytochrome C 
release following effective drug priming for cell death 
[19]. Cells treated for as little as 4 hours with TG02 had 
enhanced sensitivity to BAD-BH3 but not NOXA-BH3 
peptides (see Figure 1 for schematic diagram), suggesting 
that TG02 indeed acts in a pro-apoptotic manner that 
is complementary to BAD, most probably due to the 
depletion of MCL-1. We further showed that cells treated 
with ABT-199 were sensitive to exogenous NOXA. 
This shows that there is residual capacity in AML cells 
to allow triggering of the apoptotic response by priming 
a complementary pathway (as in Figure 1). KG-1a and 
MV4.11 cells also retained some capacity to respond 
to BAD-BH3, likely due to residual BCL-XL, which is 
targeted by BAD, but not by ABT-199. Further work is in 
progress in our laboratory to determine which other AML 
drugs have a “NOXA-like” profile, enhancing sensitivity 
to BAD, and which have a “BAD-like” profile, enhancing 
sensitivity to NOXA.
We have previously shown that inhibition of RPIIS2 
by TG02 strongly correlates with BAX activation in 
patient samples [18], indicating that the ability of TG02 
to induce apoptosis is predicated on its ability to inhibit 
the CDK9-RPIIS2 axis. The downregulation of MCL-
1 and other short half-life proteins by RPII inhibition is 
well documented [31, 32]. The lack of correlation between 
MCL-1 expression and TG02 sensitivity in patient samples 
might be explained by these indirect and variable effects. 
TG02 has a wide range of potential mediators of its anti-
tumour activity [16], and we do not assume that MCL-
1 is the single mechanistic target for TG02. However, 
the results of this report, particularly the sensitisation to 
BAD-BH3, but not to NOXA-BH3, indicate that targeting 
MCL-1 is highly relevant to its mode of action. In 
contrast, the BAD mimetic ABT-199, which specifically 
targets BCL-2, induced the activation of BAX within two 
hours in sensitive patient cells, consistent with the direct 
inhibitory mode of action of this drug. As yet ABT-199 
is not as thoroughly characterised as its first generation 
analogue ABT-737, but many of its interactions are likely 
to be similar. Resistance to ABT-737 in AML cells can be 
reversed by MCL-1 knockdown [11, 12]. Moreover the 
ABT-737 sensitivity of AML samples in vitro corresponds 
to their sensitivity to peptides derived from the BAD BH3 
domain, which binds BCL-2, but not those derived from 
the NOXA BH3 domain (which binds MCL-1) [4].
Intriguingly, whereas resistance to TG02 in 
primary AML samples is associated with high BCL-2 
expression (as shown in Figure 6), others have shown 
that resistance to ABT-199 in primary AML samples 
is associated with low BCL-2 expression [33]. The 
rationale behind a requirement for high BCL-2 for BAD 
mimetic effects has emerged from experiments in which 
ABT-737 preferentially targets BCL-2 complexed to the 
activator BH3 protein BIM, releasing BIM from BCL-
2 and subsequently activating BAX [30, 34, 35], thus 
demonstrating that BCL-2 can act as a reservoir for BH3-
only apoptosis activators. The ability of BCL-2, and likely 
also of MCL-1 [36], to act as reservoirs also helps explain 
why cellular sensitivity and expression levels do not 
necessarily correlate.
In the KG-1a cell line, we demonstrated synergy 
for TG02 with ABT-199. This was greatest at higher 
doses, and the data in Figure 4 show that the combination 
was able to effect total eradication of the cells, whereas 
apoptosis was only weakly induced by the single agents. 
After a partial response to a low dose of ABT-199, the 
curve for this agent appeared to reach a plateau, also seen 
in the patient samples in Figure 5A, attesting well to the 
high potency and specificity of this compound.
AML patient samples are heterogeneous in their 
responses to both agents, and the complementarity of 
the combination may be underpinned by synergy in 
some cases, but also by broadening the proportion of 
samples that respond. It is of note that we could reduce 
the concentration of each compound by 50% and still 
have a combination that was more effective than either 
agent alone (Figure 5C). The heterogeneity of MCL-1 and 
BCL-2 expression in primary samples, and likely even 
within individual patient isolates, suggests that it would 
be difficult to establish cut-off points that would enable 
the clinician to select patients for either MCL-1 or for 
BCL-2 targeting, and therefore the use of complementary 
agents may offer an ideal solution to this dilemma. ABT-
199 and TG02 are both currently in clinical development 
in multiple hematologic cancers and the current work 
establishes a strong rationale for the clinical assessment 
of the two agents in combination. Other agents targeting 
BCL-2 and MCL-1 have been discussed in recent reviews 
[15, 36].
We conclude that TG02 and ABT-199 are 
complementary in AML. We further conclude that 
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Dynamic BH3 Profiling, a term recently coined by 
Montero, Letai and co-workers [19], is a powerful 
technique for early prediction of drug sensitivity in 
primary samples, and may be transferrable to specialist 
diagnostic laboratories, as evidenced by publications 
analysing basal BH3 profiles of AML patient cells [29, 
37]. We have shown that the technique may also be used 
to predict complementarity at the level of apoptosis 
induction. This technique is therefore likely to have further 
widespread applicability.
MATERIALS AND METHODS
Patient cells: ethics statement
The investigation was conducted on samples 
obtained with informed consent in accordance with the 
ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board.
Patient cells: preparation
Mononuclear cells were obtained by standard 
methods from bone marrow or peripheral blood samples 
of patients with AML. Cells were cryopreserved until 
use. Only samples with >90% post-thaw viability were 
assayed.
Reagents
TG02 was obtained as a citrate salt from Tragara 
Pharmaceuticals (San Diego, USA).
ABT-199 was from Active BioChem (Hong-Kong). 
Interleukin-3 (IL-3) was a gift from Novartis (Basel, 
Switzerland). Interleukin-6 (IL-6) and stem cell factor 
and Annexin V were from R&D Systems (Abingdon, 
UK), thrombopoietin and stromal cell-derived factor 
1 from Peprotech (London, UK). Granulocyte colony 
stimulating factor (G-CSF, Neupogen) was a gift from 
Amgen. Antibodies used for flow cytometry were active 
BAX (Clone 3), active caspase 3 PE, Cytochrome C Alexa 
647 (#558709), CD34-PerCP and CD38-APC or CD38-PE 
from Becton Dickinson (Cowley, UK); active BAK (clone 
TC100/ab1, Millipore, UK), BCL-XL (#2767) from Cell 
Signalling Technologies (UK distributor New England 
Biolabs, Hitchin, UK); MCL-1 (#31948) was from Abcam 
(Cambridge, UK); BCL-2-FITC (Dako #F7053) was 
from UK distributor Alere (Stockport, UK). For Western 
blotting, rabbit polyclonal MCL-1 (S-19) (sc-819), mouse 
monoclonal BCL-2 (C-2) (sc-7382), goat anti-rabbit 
IgG-HRP (sc-2054) and goat anti-mouse IgG-HRP (sc-
2055), were all obtained from Santa Cruz UK supplier 
Insight Biotechnology, Wembley). CD2 Dynabeads were 
from Invitrogen (Paisley, UK). z-VAD-fmk was from 
Calbiochem, Nottingham, UK. Additional reagents were 
obtained from Sigma (Poole, UK) unless otherwise stated.
Cell lines and culture
The OCI-AML3 myeloid leukemia cell line was 
obtained from the German Collection of Microorganisms 
and Cell Cultures (DSMZ, Braunschweig, Germany). 
The KG-1a cell line was from the European Collection of 
Animal Cell Cultures (Salisbury, UK). The MV4.11 cell 
line was from the American Tissue Culture Collection 
(Manassas, USA). OCI-AML3 and MV4.11 cell lines 
were maintained in R10 medium and KG-1a cells in R20 
medium (i.e. RPMI 1640 medium with 10% (R10) or 20% 
(R20) foetal calf serum (FCS; First Link, Birmingham, 
UK), and 2mM L-glutamine. All cultures were kept at 37°C 
in 5% CO2 and all experiments were performed with cell 
lines in log phase. Continued testing to authenticate these 
cell lines was performed using multiplex short tandem 
repeat analysis (Powerplex 16, Promega, Southampton, 
UK). Mycoplasma testing was carried out routinely using 
the Mycoalert mycoplasma detection kit (Lonza, Rockland, 
USA) and following the manufacturer’s instructions.
Cell line toxicity assays
Cells were set up at 5 X 105/ml and cultured 
in R10 or R20 (see above) for 18-22 hours. Toxicity 
was measured using Alamar Blue (Roche, Mannheim 
Germany) according to manufacturers’ instructions.
Patient cell toxicity assays
Cells were cultured for 18-22 hours in R10 with 
20 ng/ml each of IL-3, IL-6, stem cell factor and 25 ng/
ml G-CSF, before analysis by flow cytometric viable cell 
counting using 7-amino actinomicin D (7-AAD) and fixed 
cells as internal standard for quantitation as previously 
reported [17].
Protein measurement
Protein concentrations were measured by flow 
cytometry and Western blotting.
Flow cytometry
Protein expression of MCL-1 (Abcam #31948) 
and BCL-2 (Ancell #357-040) were measured by flow 
cytometry as reported [17].
Western blotting
Cells were washed in ice cold PBS and resuspended 
in lysis buffer (50nM Tris{pH 7.4}), 150mM NaCL 
(Fisher Scientific, Loughborough, UK), 1% NP-40 
(BDH Laboratory supplies, Lutterworth, UK), 0.25% 
Na-deoxycholate, 1mM EDTA, 2μg/ml leupeptin, 5μg/
ml aprotinin, 1μg/ml pepstatin, 20mM NaF, 1mM PMSF 
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and 3mM sodium orthovanadate for 30 minutes. Samples 
were then sonicated before addition of 200mM PMSF and 
incubation for 30 minutes on ice. The protein content in 
the lysate was determined using Bio-Rad dye reagent and 
resolved by SDS-PAGE. After transfer to a nitrocellulose 
membrane and blocking in 5% non-fat milk, immunoblotting 
was carried out with the antibodies described above. Proteins 
were visualized using chemiluminescence (Hyperfilm ECL; 
Amersham). The intensity of the signal was analyzed by 
Adobe Photoshop CC 2014 software.
BH3 profiling
Cytochrome C release was measured by flow 
cytometry after incubation of digitonin-permeabilised cells 
with BH3 peptides as described [33]. BH3 peptides were 
synthesised by GenScript using published sequences [21]. 
Reactivities were temperature dependent and were carried 
out at 23-25°C. Results in patient cells were only deemed 
valid where cell viability as determined by cytochrome C 
release in the presence of the mutated BH3 peptide Puma2A 
(100 μM) was less than 10% and release of cytochrome C 
in the presence of 10 μM BIM-BH3 as positive control was 
greater than 90%. In patient cell analysis CD45/side-scatter 
gating was used to exclude lymphocytes. Adjustments for 
peptide induced cytochrome C release in untreated cells 
were made in order to establish agent-specific release, 
using the formula 100*(release with agent – release without 
agent)/(100 – release without agent).
Detection of apoptotic pathways
Active BAX was measured using the Transduction 
labs clone 3 BAX antibody which recognises a 
conformationally active epitope [9, 26] in cells which 
had been fixed and permeabilised using the Leucoperm 
kit from AbD Serotec. Leucoperm was also used to 
permeabilise cells for active caspase 3 measurement. 
Active BAK (clone TC100/ab1, [38]) was measured in 
cells fixed in 0.25% formaldehyde and permeabilised with 
0.05% digitonin as previously reported [39].
Statistics
Statistics were carried out using SPSS version 21 
software (Chicago, IL, USA). Univariate analysis of 
variance was used for analysis of cell lines. Where patient 
data was seen to be non-parametrically distributed it was 
analysed accordingly, i.e with Wilcoxon signed rank 
tests or Mann Whitney analysis. P values <0.05 were 
considered statistically significant.
Synergy calculations
Synergy was determined using Calcusyn Software 
to perform Chou and Talalay analysis [24] for interactions 
between compounds.
mRNA measurement
MCL-1, BCL-2 and beta 2 microglobulin (B2M) 
expression were measured by realtime PCR of RNA 
prepared from CD2-depleted samples from untreated 
patients exactly as previously reported [17].
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